Pharmaceutical company Adcock Ingram has set its sights on potential acquisitions in the personal care and baby care segments in a move to reduce exposure to health-care regulations in the country, says CEO Andy Hall. Through the single exit price mechanism, private sector medicine prices are tightly controlled and manufacturers can only hike prices in line with adjustments determined by the department’s medicine pricing committee, usually done once a year. This means they cannot pass increased input costs onto consumers, putting pressure on their margins. The single exit price mechanism lists the maximum price that a medicine can be charged at. Speaking after the release of the company’s results for the year to June, Hall said Adcock was looking for growth away from the regulated segments of the industry. As a result of the appetite for acquisition, Adcock has chosen cash preservation over generous dividends. Hall said the company would stick to its dividend policy of two to three ...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now